Ibrahim Turkoz, PhD

Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia

September 25, 2023

Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...

Oliver J. Lopena, Larry D. Alphs, Martha Sajatovic, et al

Original Research

Response to Esketamine After Initial Nonresponse

July 20, 2021

Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate...

Ibrahim Turkoz, Ella Daly, Jaskaran Singh, et al

Original Research

Half-Life After Antipsychotic Discontinuation

August 23, 2017

Read the results on whether a longer half-life is associated with longer time to relapse after antipsychotic discontinuation, even among LAI formulations.

Ibrahim Turkoz, Peter J. Weiden, Edward Kim, et al

Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

Ibrahim Turkoz, Jean-Pierre Lindenmayer, David P. Walling, et al

Letter to the Editor

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

October 15, 2012

Ibrahim Turkoz, Larry Alphs, William H. Olson, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

May 15, 2010

Cynthia A. Bossie, Ibrahim Turkoz, Jean-Pierre Lindenmayer, et al

Original Research

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

August 15, 2006

Cynthia A. Bossie, Ibrahim Turkoz, Ramy A. Mahmoud, et al

Letter to the Editor

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

January 16, 2006

Cynthia A. Bossie, Ibrahim Turkoz, Georges M. Gharabawi, et al

Original Research

Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder

February 15, 2005

Ibrahim Turkoz, Rohan Ganguli, Jaspreet S. Brar, et al

Original Research

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

March 1, 2004

Glenn W. Currier, James C-Y Chou, David Feifel, et al

Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia

Response to Esketamine After Initial Nonresponse

Half-Life After Antipsychotic Discontinuation

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

ELSEWHERE:

FOLLOW US:

Ibrahim Turkoz, PhD

Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia

Response to Esketamine After Initial Nonresponse

Half-Life After Antipsychotic Discontinuation

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Subscribe to readmore articles

Subscribe to read
more articles